CA3091647A1 - Methods for prostate cancer detection and treatment - Google Patents

Methods for prostate cancer detection and treatment Download PDF

Info

Publication number
CA3091647A1
CA3091647A1 CA3091647A CA3091647A CA3091647A1 CA 3091647 A1 CA3091647 A1 CA 3091647A1 CA 3091647 A CA3091647 A CA 3091647A CA 3091647 A CA3091647 A CA 3091647A CA 3091647 A1 CA3091647 A1 CA 3091647A1
Authority
CA
Canada
Prior art keywords
score
expression level
subject
tmprss2
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3091647A
Other languages
English (en)
French (fr)
Inventor
Irvin Mark MODLIN
Mark Kidd
Ignat Drozdov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquid Biopsy Research LLC
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of CA3091647A1 publication Critical patent/CA3091647A1/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3091647A 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment Pending CA3091647A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633675P 2018-02-22 2018-02-22
US62/633,675 2018-02-22
PCT/US2019/018878 WO2019165021A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Publications (1)

Publication Number Publication Date
CA3091647A1 true CA3091647A1 (en) 2019-08-29

Family

ID=65686083

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3091647A Pending CA3091647A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Country Status (15)

Country Link
US (3) US11410748B2 (cg-RX-API-DMAC7.html)
EP (2) EP3755816B1 (cg-RX-API-DMAC7.html)
JP (2) JP7662337B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260018206A (cg-RX-API-DMAC7.html)
CN (2) CN119932188A (cg-RX-API-DMAC7.html)
AU (2) AU2019224025B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016989A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091647A1 (cg-RX-API-DMAC7.html)
DK (1) DK3755816T3 (cg-RX-API-DMAC7.html)
ES (1) ES3023842T3 (cg-RX-API-DMAC7.html)
IL (1) IL276748A (cg-RX-API-DMAC7.html)
MX (2) MX2020008702A (cg-RX-API-DMAC7.html)
PL (1) PL3755816T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202007922XA (cg-RX-API-DMAC7.html)
WO (1) WO2019165021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901819A (zh) 2019-10-10 2022-08-12 液体活检研究有限责任公司 用于生物样品和rna稳定化的组合物、方法和试剂盒
JP7757291B2 (ja) * 2020-02-06 2025-10-21 オンコホスト リミテッド 治療法応答の機械学習予測
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
JP2025534688A (ja) 2022-10-12 2025-10-17 リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー 唾液において前立腺癌を検出するための方法
GB2623570B (en) * 2022-10-21 2025-07-23 Wobble Genomics Ltd Method and products for biomarker identification
KR102891032B1 (ko) * 2022-12-29 2025-12-03 재단법인대구경북과학기술원 혈액 단구세포 전사체 생체표지자를 이용한 전이성 전립선암 진단용 바이오마커 및 이의 용도
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用
CN119964650B (zh) * 2024-12-24 2025-09-30 深圳大学 一种基于集成学习的基因调控网络推断方法和系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271232A1 (en) * 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
IL243203A (en) * 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
DK3179393T3 (da) * 2012-01-31 2020-07-27 Genomic Health Inc Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
HK1210230A1 (en) * 2012-07-20 2016-04-15 戴格努生命科学公司 Methods, kits and compositions for providing a clinical assessment of prostate cancer
US10081842B2 (en) * 2012-08-07 2018-09-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene expression profiles
KR20150110477A (ko) * 2012-11-20 2015-10-02 파디아 에이비 공격적인 전립선 암의 존재 또는 부존재를 나타내는 방법
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
JP2016521966A (ja) * 2013-03-15 2016-07-28 メタマーク ジェネティクス, インコーポレイテッド 癌の予後のための組成物および方法
US20160130661A1 (en) * 2013-06-13 2016-05-12 University Of South Australia Methods for detecting prostate cancer
CA2920429C (en) 2013-08-06 2021-11-16 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
EP3214444A1 (en) * 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means

Also Published As

Publication number Publication date
ES3023842T3 (en) 2025-06-03
SG11202007922XA (en) 2020-09-29
AU2019224025A1 (en) 2020-09-10
EP3755816A1 (en) 2020-12-30
US20260066046A1 (en) 2026-03-05
US20230298695A1 (en) 2023-09-21
US20190259471A1 (en) 2019-08-22
JP2021514624A (ja) 2021-06-17
AU2025238057A1 (en) 2025-11-27
MX2020008702A (es) 2020-09-25
CN112673115B (zh) 2025-02-18
KR102921718B1 (ko) 2026-02-03
KR20260018206A (ko) 2026-02-06
AU2019224025B2 (en) 2025-06-26
IL276748A (en) 2020-10-29
EP3755816B1 (en) 2025-02-12
WO2019165021A1 (en) 2019-08-29
CN112673115A (zh) 2021-04-16
KR20200123450A (ko) 2020-10-29
CN119932188A (zh) 2025-05-06
BR112020016989A2 (pt) 2020-12-29
DK3755816T3 (da) 2025-04-28
JP2025096376A (ja) 2025-06-26
EP4538393A3 (en) 2025-07-02
JP7662337B2 (ja) 2025-04-15
MX2025000449A (es) 2025-03-07
US11410748B2 (en) 2022-08-09
PL3755816T3 (pl) 2025-06-30
EP4538393A2 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
US20260066046A1 (en) Methods for prostate cancer detection and treatment
US12305240B2 (en) Methods for colon cancer detection and treatment
JP7724265B2 (ja) 遺伝子発現アッセイを使った予測ペプチド受容体放射性核種療法
HK40043345B (en) Methods for prostate cancer detection and treatment
HK40043345A (en) Methods for prostate cancer detection and treatment
HK40042084B (en) Methods for colon cancer detection and treatment monitoring
HK40042084A (en) Methods for colon cancer detection and treatment monitoring
HK40035975A (en) Predicting peptide receptor radiotherapy using a gene expression assay
HK40035975B (en) Predicting peptide receptor radiotherapy using a gene expression assay

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250210

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250210

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250722

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260107

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260209